. . . "colorectal cancer; palliative chemotherapy; raltitrexed oxaliplatin"@en . . "Demlov\u00E1, Regina" . "14110" . . "Jarkovsk\u00FD, Ji\u0159\u00ED" . . "[0D1413375900]" . "Z(MZ0MOU2005)" . . "RIV/00216224:14110/06:00039991!RIV10-MZ0-14110___" . "Neoplasma" . "RIV/00216224:14110/06:00039991" . . . . . "Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer."@en . "Koc\u00E1kov\u00E1, Ilona" . "0028-2685" . . . "496379" . "The primary endpoint of this study was to evaluate the efficacy (objective response rate; ORR) of combined chemotherapy with raltitrexed plus oxaliplatin as second-line treatment in patients with metastatic colorectal cancer (CRC). Secondary endpoints were overall survival (OS), time to progression (TTP) and toxicity (NCI-CTC criteria). The target population were patients with metastatic colorectal adenocarcinoma who progressed after first-line chemotherapy. Treatment consisted of raltitrexed 3 mg/m(2) as a 15-minute intravenous (IV) infusion followed 45 minutes later by oxaliplatin 130 mg/m(2) IV as a 2-h infusion on Day 1, repeated every 3 weeks until further disease progression (PD), unacceptable toxicity or the decision of the patient. A total of 51 patients, all with WHO performance status 0-2 received a median of 6 treatment cycles (range 1-11). After 3 cycles, 8 of the 47 evaluable patients (17%) had experienced an ORR, 28 patients (59." . "SK - Slovensk\u00E1 republika" . . . "9"^^ . . "53" . "6"^^ . . "Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer."@en . "Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer." . "6"^^ . "Du\u0161ek, Ladislav" . "The primary endpoint of this study was to evaluate the efficacy (objective response rate; ORR) of combined chemotherapy with raltitrexed plus oxaliplatin as second-line treatment in patients with metastatic colorectal cancer (CRC). Secondary endpoints were overall survival (OS), time to progression (TTP) and toxicity (NCI-CTC criteria). The target population were patients with metastatic colorectal adenocarcinoma who progressed after first-line chemotherapy. Treatment consisted of raltitrexed 3 mg/m(2) as a 15-minute intravenous (IV) infusion followed 45 minutes later by oxaliplatin 130 mg/m(2) IV as a 2-h infusion on Day 1, repeated every 3 weeks until further disease progression (PD), unacceptable toxicity or the decision of the patient. A total of 51 patients, all with WHO performance status 0-2 received a median of 6 treatment cycles (range 1-11). After 3 cycles, 8 of the 47 evaluable patients (17%) had experienced an ORR, 28 patients (59."@en . "Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer." . "2" . "Vyzula, Rostislav" . . . . "Kiss, Igor" .